Literature DB >> 24312791

Lactose engineering for better performance in dry powder inhalers.

Yahya Rahimpour1, Hamed Hamishehkar.   

Abstract

Dry powder inhaler (DPI) is generally formulated as a powder mixture of coarse carrier particles and micronized drug with aerodynamic diameters of 1-5 μm. Carrier particles are used to improve drug particle flowability, thus improving dosing accuracy, minimizing the dose variability compared with drug alone and making them easier to handle during manufacturing operations. Lactose is the most common and frequently used carrier in DPIs formulations and nowadays various inhalation grades of lactose with different physico-chemical properties are available on the market. Therefore, the purpose of this manuscript is to review evolution of lactose as a carrier in inhalable formulations, their production and the impact of its physico-chemical properties on drug dispersion. This review offers a perspective on the current reported studies to modify lactose for better performance in DPIs.

Entities:  

Keywords:  Carrier; Dry powder inhaler; Lactose; Pulmonary drug delivery

Year:  2012        PMID: 24312791      PMCID: PMC3845988          DOI: 10.5681/apb.2012.028

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  39 in total

Review 1.  In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.

Authors:  Masahiro Sakagami
Journal:  Adv Drug Deliv Rev       Date:  2006-08-15       Impact factor: 15.470

Review 2.  Potential therapeutic targets for Parkinson's disease.

Authors:  Jon Stoessl
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

3.  Spray dried mannitol carrier particles with tailored surface properties--the influence of carrier surface roughness and shape.

Authors:  E M Littringer; A Mescher; H Schroettner; L Achelis; P Walzel; N A Urbanetz
Journal:  Eur J Pharm Biopharm       Date:  2012-05-14       Impact factor: 5.571

4.  The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate.

Authors:  G P Martin; C Marriott; J Pritchard
Journal:  Eur J Pharm Biopharm       Date:  2001-01       Impact factor: 5.571

5.  The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.

Authors:  Waseem Kaialy; Hassan Larhrib; Gary P Martin; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

Review 6.  Dry powder inhalers: an overview.

Authors:  Paul J Atkins
Journal:  Respir Care       Date:  2005-10       Impact factor: 2.258

7.  Alternative sugars as potential carriers for dry powder inhalations.

Authors:  Hartwig Steckel; Nina Bolzen
Journal:  Int J Pharm       Date:  2004-02-11       Impact factor: 5.875

8.  Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.

Authors:  Kotaro Iida; Youhei Hayakawa; Hirokazu Okamoto; Kazumi Danjo; Hans Luenberger
Journal:  Chem Pharm Bull (Tokyo)       Date:  2004-03       Impact factor: 1.645

9.  Inhaled azithromycin therapy.

Authors:  Anthony J Hickey; Dongmei Lu; Elizabeth Dodds Ashley; Jason Stout
Journal:  J Aerosol Med       Date:  2006

10.  Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy.

Authors:  Carl Plumley; Eric M Gorman; Nashwa El-Gendy; Connor R Bybee; Eric J Munson; Cory Berkland
Journal:  Int J Pharm       Date:  2008-10-25       Impact factor: 5.875

View more
  7 in total

1.  Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery.

Authors:  Mehdi Hassanpour Aghdam; Saeed Ghanbarzadeh; Yousef Javadzadeh; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2016-03-17

Review 2.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

3.  Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations.

Authors:  Adam Pacławski; Jakub Szlęk; Raymond Lau; Renata Jachowicz; Aleksander Mendyk
Journal:  Int J Nanomedicine       Date:  2015-01-21

4.  Dramatic improvement in dissolution rate of albendazole by a simple, one-step, industrially scalable technique.

Authors:  Saeed Ghanbarzadeh; Aram Khalili; Abolghasem Jouyban; Shahram Emami; Yousef Javadzadeh; Mohammad Solhi; Hamed Hamishehkar
Journal:  Res Pharm Sci       Date:  2016-12

5.  A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.

Authors:  Tair Lapidot; Mohammed Bouhajib; Janice Faulknor; Shabaz Khan; Galia Temtsin Krayz; Carolina Abrutzky; Dalia Megiddo
Journal:  Pharm Res       Date:  2022-04-06       Impact factor: 4.580

Review 6.  Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections.

Authors:  Mohammad Zaidur Rahman Sabuj; Nazrul Islam
Journal:  Nanoscale Adv       Date:  2021-05-17

7.  Concept review of dry powder inhalers: correct interpretation of published data.

Authors:  David Price; Henry Chrystyn
Journal:  Multidiscip Respir Med       Date:  2015-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.